Wave Life Sciences Duchenne Muscular Dystrophy Clinical

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
45
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program

Suvodirsen (WVE-210201) Phase 2/3 trial chosen in inaugural round of pilot program

FDA pilot program is a 21 st Century Cures Act initiative

CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the planned Phase 2/3 efficacy and safety trial for its lead Duchenne muscular dystrophy (DMD) clinical program has been selected for the U.S. Food and Drug Administration (FDA) pilot program for complex innovative trial designs (CID). The selection was based on the design of Wave’s Phase 2/3 clinical trial of suvodirsen (WVE-210201), an investigational therapy for boys with DMD who are amenable to exon 51 skipping. This marks the first time that the FDA has selected clinical protocols for its CID pilot program that was announced in August 2018.

In evaluating submissions for the CID pilot program, the FDA considered two key criteria: the innovative features of the trial design and the therapeutic need (i.e., therapies being developed for use in disease areas where there are limited or no treatment options). Wave’s application for the CID pilot program includes a plan to leverage DMD historical control data to augment the placebo arm of the suvodirsen Phase 2/3 clinical trial, among other innovative design elements. Through this pilot program, Wave intends to reduce the number of patients required to deliver conclusive clinical efficacy results, thereby minimizing the number of patients required in the placebo treatment arm and potentially accelerating study completion. As a participant in the pilot program, the company will also have additional opportunities to meet with FDA staff to discuss the design elements of the trial, including the use of Bayesian methods to adapt the trial and allow for more efficient and productive clinical determinations. Details of Wave’s Phase 2/3 trial design will be presented at upcoming scientific meetings.

“In designing our clinical trials, we are constantly looking to maximize the probability of a definitive result, incorporate the feedback of patients and their families, and reduce the burden on those who are already bravely enduring the challenges associated with serious, genetically-defined diseases. The FDA’s recognition of our plan reflects the thoughtful and collaborative way in which we approach clinical development,” said Michael Panzara, MD, MPH, Chief Medical Officer of Wave Life Sciences. “We look forward to further discussions with the FDA in the coming months and sharing learnings from our trial design with others in the rare disease drug development community to drive greater efficiency and productivity in future clinical studies.”

Wave anticipates initiating the global, placebo-controlled Phase 2/3 efficacy and safety clinical trial of suvodirsen in DMD patients amenable to exon 51 skipping in 2019. The trial is designed to measure clinical efficacy and dystrophin expression, and Wave intends to use the results of this trial to seek regulatory approvals globally. Currently, suvodirsen is being studied in an ongoing open-label extension (OLE) study and Wave expects to deliver an interim analysis of dystrophin expression from this study in the second half of 2019.

The FDA CID pilot program is an initiative under the 21 st Century Cures Act, with an objective to modernize clinical trial design, help streamline and advance drug development and inform easier regulatory decision-making. In order to qualify for the CID pilot program, companies must intend to provide substantial evidence of efficacy through a complex, novel design that incorporates innovative trial design elements such as seamless trial designs, modeling and simulations to assess trial operating characteristics, the use of biomarker enriched populations, complex adaptive designs, Bayesian models and other benefit-risk determinations, among others. For more information, visit https://www.fda.gov/Drugs/DevelopmentApproval...617212.htm .

About Duchenne Muscular Dystrophy Duchenne muscular dystrophy (DMD) is a fatal X-linked genetic neuromuscular disorder caused predominantly by out-of-frame deletions in the dystrophin gene, resulting in absent or defective dystrophin protein. Dystrophin protein is needed for normal muscle maintenance and operation. Because of the genetic mutations in DMD, the body cannot produce functional dystrophin, which results in progressive and irreversible loss of muscle function, including the heart and lungs. Globally, DMD affects approximately one in 5,000 newborn boys.

About Suvodirsen (WVE-210201) Suvodirsen is an investigational stereopure oligonucleotide that has been shown to induce skipping of exon 51 of dystrophin pre-mRNA in preclinical studies and is intended for the treatment of Duchenne muscular dystrophy (DMD). Approximately 13% of DMD patients have genetic mutations that are amenable to treatment with an exon 51 skipping therapy. Exon-skipping technology has the potential to induce cellular machinery to ‘skip over’ a targeted exon and restore the reading frame, resulting in the production of internally truncated, but functional dystrophin protein. Wave preclinical in vitro experiments using gymnotic delivery (free uptake) of suvodirsen in DMD patient-derived myoblasts demonstrated efficient exon 51 skipping and dystrophin protein restoration. Preclinical Western blot studies of suvodirsen demonstrated 52% dystrophin protein restoration compared with normal skeletal muscle tissue lysates. Suvodirsen has been granted orphan drug designation for the treatment of DMD by the U.S. Food and Drug Administration (FDA) and the European Commission, as well as rare pediatric disease designation by the FDA.

About Suvodirsen (WVE-210201) Clinical Trials Suvodirsen is being studied in a global, multicenter, double-blind, placebo-controlled Phase 1 clinical trial designed to evaluate the safety, tolerability and plasma concentrations of single ascending doses of suvodirsen administered intravenously in Duchenne muscular dystrophy patients with gene mutations amenable to exon 51 skipping. The trial is expected to enroll up to 40 patients, including ambulatory and non-ambulatory patients between 5 and 18 years of age. In December 2018, the company announced that, based on results from four ascending dose cohorts in the Phase 1 clinical trial, the safety and tolerability profile of suvodirsen supports initiation of a Phase 2/3 clinical trial.

As patients complete the Phase 1 trial, they have the option to enroll in an ongoing open-label extension (OLE) study in which they receive suvodirsen. The company remains on track to deliver an interim analysis of dystrophin expression from muscle biopsies in boys receiving suvodirsen in the OLE study in the second half of 2019. Data from this analysis are intended to be an important component of a submission to the U.S. Food and Drug Administration for accelerated approval in the United States.

About Wave Life Sciences Wave Life Sciences is a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases. Its chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. The company’s pipeline is initially focused on neurological disorders and extends across several other therapeutic areas. For more information, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci .

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the potential benefits of being selected to participate in the FDA’s pilot program for complex innovative trial designs, the expected timing of initiation of a suvodirsen Phase 2/3 clinical trial, the plans to present details of the suvodirsen Phase 2/3 trial design at upcoming scientific meetings, the expected timing of an interim analysis of dystrophin expression from muscle biopsies in boys receiving suvodirsen in the OLE study, and Wave’s intention to use the results of the Phase 2/3 trial to seek regulatory approvals globally.  The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Investor Contact:

Graham Morrell 781-686-9600 gmorrell@wavelifesci.com

Media Contact:

Jose Juves 617-949-4708 jjuves@wavelifesci.com

Patient Contact:

Wendy Erler 617-949-2898 werler@wavelifesci.com  

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 18

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
COFE+ Barista Test Puts Robotic Coffee on the Clock

Updated Category News Views 84

A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 13

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 55

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 68

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 149

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 26

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 79

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 78

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading

Top 5 Most Recently Viewed Articles

CMG Teams Up with NVIDIA for Enhanced Simulation Technology

Updated Category News Views 70

Innovative Partnership for Advanced Simulation Solutions Computer Modelling Group Ltd. (CMG) is embarking on a transformative journey by collaborating with NVIDIA, aiming to revolutionize their subsurface simulation solutions. This partnership is set to enhance speed, performance, and energy efficiency, showcasing CMG's commitment to staying at the forefront of...

Continue Reading
Understanding P/E Ratios: A Deep Dive into Zimmer Biomet Holdings

Updated Category News Views 224

Understanding P/E Ratios and Their Importance The price-to-earnings (P/E) ratio is a vital metric in assessing a company's valuation. Current trading for Zimmer Biomet Holdings Inc. (ZBH) shares has reached $97.99, reflecting a noteworthy increase of 1.52%. Over the past month, this stock has climbed by 5.16%, contrasting a year-over-year decline of 12.03%. Investors are...

Continue Reading
Breakthrough Outcomes of Telitacicept in Sjögren's Syndrome Study

Updated Category News Views 220

Exciting Developments in Telitacicept Phase III Trial Results The Phase III clinical trial results for Telitacicept are sparking significant interest, particularly within the realm of Sjögren's Syndrome. This autoimmune condition can severely affect patients' quality of life due to symptoms like dry mouth and dry eyes, among others. Recently, announcements surrounding...

Continue Reading
BioCryst Pharmaceuticals Shares Mixed Q4 Earnings and Trial Insights

Updated Category News Views 234

Promising Results from BioCryst Pharmaceuticals' APeX-P Trial BioCryst Pharmaceuticals, Inc. has recently revealed noteworthy findings from the interim analysis of its APeX-P trial. This ongoing study focuses on an innovative oral granule formulation of Orladeyo (berotralstat) designed for once-daily use in pediatric patients suffering from hereditary angioedema (HAE)....

Continue Reading
Supermicro Reveals Advanced Server Design for Edge AI Solutions

Updated Category News Views 109

Supermicro Unveils New Infrastructure for AI Efficiency Super Micro Computer, Inc. (SMCI) has recently launched an innovative 3U server designed to support up to 18 GPUs while integrating dual Intel® Xeon® 6900 series processors equipped with P-cores. This powerful system is strategically engineered for artificial intelligence inferencing at the edge, meeting the...

Continue Reading